BRST5:Volunteer Assignments and Opportunities: Difference between revisions

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(43 intermediate revisions by 5 users not shown)
Line 6: Line 6:


To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
 
__TOC__
<br />
<br />
{| class="wikitable" style="margin:auto"
{| class="wikitable" style="margin:auto"
Line 19: Line 19:
!'''Notes'''
!'''Notes'''
|-
|-
|CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST)
|
====CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST)====
|
|
----
----
Line 39: Line 40:
----
----
|-
|-
|Usual ductal hyperplasia
|[[BRST5:Usual ductal hyperplasia|Usual ductal hyperplasia]]
|Disease
|Disease
|Ritika Pathak
|2/25/2026
|
|
|PENDING
|
|
|
|Katherine Geiersbach
|
|
|
|
|
|
|
|-
|-
|Columnar cell lesions, including flat epithelial atypia||Disease||
|[[BRST5:Columnar cell lesions, including flat epithelial atypia|Columnar cell lesions, including flat epithelial atypia]]||Disease||
|
|
|
|
Line 59: Line 60:
|
|
|-
|-
|Atypical ductal hyperplasia||Disease||
|[[BRST5:Atypical ductal hyperplasia|Atypical ductal hyperplasia]]||Disease||
|
|
|
|
Line 68: Line 69:
|
|
|-
|-
|Sclerosing adenosis||Disease||
|[[BRST5:Sclerosing adenosis|Sclerosing adenosis]]||Disease||
|
|
|
|
Line 77: Line 78:
|
|
|-
|-
|Apocrine adenosis and adenoma||Disease||
|[[BRST5:Apocrine adenosis and adenoma|Apocrine adenosis and adenoma]]||Disease||
|
|
|
|
Line 86: Line 87:
|
|
|-
|-
|Microglandular adenosis||Disease||
|[[BRST5:Microglandular adenosis|Microglandular adenosis]]||Disease||
|
|
|
|
Line 95: Line 96:
|
|
|-
|-
|Radial scar/complex sclerosing lesion||Disease||
|[[BRST5:Radial scar / complex sclerosing lesion|Radial scar/complex sclerosing lesion]]||Disease||
|
|
|
|
Line 104: Line 105:
|
|
|-
|-
|Tubular adenoma||Disease||
|[[BRST5:Tubular adenoma|Tubular adenoma]]||Disease||
|
|
|
|
Line 113: Line 114:
|
|
|-
|-
|Lactating adenoma||Disease||
|[[BRST5:Lactating adenoma|Lactating adenoma]]||Disease||Joanna George
|
|3/28/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
|-
|-
|Ductal adenoma||Disease||
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Ductal adenoma|Ductal adenoma]]||Disease||
|
|
|
|
Line 131: Line 143:
|
|
|-
|-
|Pleomorphic adenoma||Disease||
|[[BRST5:Pleomorphic adenoma|Pleomorphic adenoma]]||Disease||
|
|
|
|
Line 140: Line 152:
|
|
|-
|-
|Adenomyoepithelioma||Disease||
|[[BRST5:Adenomyoepithelioma|Adenomyoepithelioma]]||Disease||
|
|
|
|
Line 149: Line 161:
|
|
|-
|-
|Malignant adenomyoepithelioma||Disease||
|[[BRST5:Malignant adenomyoepithelioma|Malignant adenomyoepithelioma]]||Disease||
|
|
|
|
Line 158: Line 170:
|
|
|-
|-
|Intraductal papilloma||Disease||
|[[BRST5:Intraductal papilloma|Intraductal papilloma]]||Disease||
|
|
|
|
Line 167: Line 179:
|
|
|-
|-
|Papillary ductal carcinoma in situ||Disease||
|[[BRST5:Papillary ductal carcinoma in situ|Papillary ductal carcinoma in situ]]||Disease||Sresi Singh (trainee), Katherine Geiersbach
|
|2/26/2026
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
|-
|-
|Encapsulated papillary carcinoma||Disease||
|[[BRST5:Encapsulated papillary carcinoma|Encapsulated papillary carcinoma]]||Disease||
|
|
|
|
Line 185: Line 197:
|
|
|-
|-
|Solid papillary carcinoma (in situ and invasive)||Disease||
|[[BRST5:Solid papillary carcinoma (in situ and invasive)|Solid papillary carcinoma (in situ and invasive)]]||Disease||
|
|
|
|
Line 194: Line 206:
|
|
|-
|-
|Invasive papillary carcinoma||Disease||
|[[BRST5:Invasive papillary carcinoma|Invasive papillary carcinoma]]||Disease||
|
|
|
|
Line 203: Line 215:
|
|
|-
|-
|Atypical lobular hyperplasia||Disease||
|[[BRST5:Atypical lobular hyperplasia|Atypical lobular hyperplasia]]||Disease||
|
|
|
|
Line 212: Line 224:
|
|
|-
|-
|Lobular carcinoma in situ||Disease||
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Lobular carcinoma in situ|Lobular carcinoma in situ]]||Disease||Vaishnavi Devarakonda
|2/19/2026
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
|-
|[[BRST5:Ductal carcinoma in situ|Ductal carcinoma in situ]]||Disease||Vaishnavi Devarakonda
|2/19/2026
|
|
|PENDING
|
|Katherine Geiersbach
|
|
|
|
|-
|-
|Ductal carcinoma in situ||Disease||
|[[BRST5:Invasive breast carcinoma of no special type|Invasive breast carcinoma of no special type]]||Disease||Braa Elwaleed Mohamed Ahmed (trainee) +Katherine to find mentor
|
|2/20/2026
|
|
|
|
|PENDING
|
|
|Katherine Geirsbach
|
|
|
|
|-
|-
|Invasive breast carcinoma of no special type||Disease||
|[[BRST5:Microinvasive carcinoma|Microinvasive carcinoma]]||Disease||
|
|
|
|
Line 239: Line 271:
|
|
|-
|-
|Microinvasive carcinoma||Disease||
|[[BRST5:Invasive lobular carcinoma|Invasive lobular carcinoma]]||Disease||
|
|
|
|
Line 248: Line 280:
|
|
|-
|-
|Invasive lobular carcinoma||Disease||
|[[BRST5:Tubular carcinoma|Tubular carcinoma]]||Disease||Sree Vishmaya
|
|3/20/2026
|
|
|
|
|
|
|
|Katherine Geiersbach
|
|
|
|
|-
|-
|Tubular carcinoma||Disease||
|[[BRST5:Cribriform carcinoma|Cribriform carcinoma]]||Disease||
|
|
|
|
Line 266: Line 298:
|
|
|-
|-
|Cribriform carcinoma||Disease||
|[[BRST5:Mucinous carcinoma|Mucinous carcinoma]]||Disease||
|
|
|
|
Line 275: Line 307:
|
|
|-
|-
|Mucinous carcinoma||Disease||
|[[BRST5:Mucinous cystadenocarcinoma|Mucinous cystadenocarcinoma]]||Disease||
|
|
|
|
Line 284: Line 316:
|
|
|-
|-
|Mucinous cystadenocarcinoma||Disease||
|[[BRST5:Invasive micropapillary carcinoma|Invasive micropapillary carcinoma]]||Disease||
|
|
|
|
Line 293: Line 325:
|
|
|-
|-
|Invasive micropapillary carcinoma||Disease||
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Carcinoma with apocrine differentiation|Carcinoma with apocrine differentiation]]||Disease||
|
|
|
|
Line 302: Line 345:
|
|
|-
|-
|Carcinoma with apocrine differentiation||Disease||
|[[BRST5:Metaplastic carcinoma|Metaplastic carcinoma]]||Disease||
|
|
|
|
Line 311: Line 354:
|
|
|-
|-
|Metaplastic carcinoma||Disease||
|[[BRST5:Acinic cell carcinoma|Acinic cell carcinoma]]||Disease||
|
|
|
|
Line 320: Line 363:
|
|
|-
|-
|[[BRST5:Acinic Cell Carcinoma|Acinic cell carcinoma]]||Disease||Patricija Zot
|[[BRST5:Adenoid cystic carcinoma|Adenoid cystic carcinoma]]||Disease||Katherine Geiersbach;
|2/28/2024
Jun Liao
|
|PENDING
|
|Katherine Geiersbach
|
|
|-
|[[BRST5:Adenoid Cystic Carcinoma|Adenoid cystic carcinoma]]||Disease||Katherine Geiersbach / Jun Liao
|10/12/02022
|10/12/02022
|11/11/2023
|11/11/2023
|COMPLETE
|COMPLETE
|
|
|Hui Chen / Katherine Geiersbach
|Katherine Geiersbach
|12/6/2023
|4/16/2025
|2021 template added
|2024 template added
|-
|-
|[[BRST5:Secretory Carcinoma|Secretory carcinoma]]||Disease||Hui Chen / Morteza Seifi
|[[BRST5:Secretory carcinoma|Secretory carcinoma]]||Disease||Hui Chen;
Katherine Geiersbach
|10/12/2022
|10/12/2022
|11/11/2023
|11/11/2023
Line 344: Line 380:
|
|
|Katherine Geiersbach
|Katherine Geiersbach
|
|4/16/2025
|2021 template added
|2024 template added
|-
|-
|Mucoepidermoid carcinoma||Disease||
|[[BRST5:Mucoepidermoid carcinoma|Mucoepidermoid carcinoma]]||Disease||
|
|
|
|
Line 356: Line 392:
|
|
|-
|-
|Polymorphous adenocarcinoma||Disease||
|[[BRST5:Polymorphous adenocarcinoma|Polymorphous adenocarcinoma]]||Disease||
|
|
|
|
Line 365: Line 401:
|
|
|-
|-
|[[BRST5:Tall Cell Carcinoma with Reversed Polarity|Tall cell carcinoma with reversed polarity]]||Disease||H. Evin Gulbahce
|[[BRST5:Tall cell carcinoma with reversed polarity|Tall cell carcinoma with reversed polarity]]||Disease||H. Evin Gulbahce
|8/11/2023
|8/11/2023
|10/11/2023
|10/11/2023
Line 371: Line 407:
|
|
|Katherine Geiersbach
|Katherine Geiersbach
|
|4/16/2025
|2021 template added
|2024 template added
|-
|-
|Neuroendocrine tumour||Disease||
|[[BRST5:Neuroendocrine tumour|Neuroendocrine tumour]]||Disease||
|
|
|
|
Line 383: Line 419:
|
|
|-
|-
|Neuroendocrine carcinoma||Disease||
|[[BRST5:Neuroendocrine carcinoma|Neuroendocrine carcinoma]]||Disease||
|
|
|
|
Line 392: Line 428:
|
|
|-
|-
|CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST)
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|
====CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST)====
|
|
----
----
Line 412: Line 460:
----
----
|-
|-
|Hamartoma||Disease||
|[[BRST5:Hamartoma|Hamartoma]]||Disease||
|
|
|
|
Line 421: Line 469:
|
|
|-
|-
|[[BRST5:Fibroadenoma|Fibroadenoma]]||Disease||H. Evin Gulbahce / Patricija Zot
|[[BRST5:Fibroadenoma|Fibroadenoma]]|| Disease||Aamer Ahmed Fairoze (trainee), Katherine Geiersbach as mentor
|8/11/2023
|2/20/2026
|11/11/2023
|
|PENDING
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
|2021 template added
|-
|-
|[[BRST5:Phyllodes Tumour|Phyllodes tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach
|[[BRST5:Phyllodes tumour|Phyllodes tumour]]||Disease||Emilie Lalonde;
H. Evin Gulbahce;
 
Katherine Geiersbach
|8/11/2023
|8/11/2023
|11/11/2023
|11/11/2023
Line 436: Line 487:
|
|
|
|
|1/8/2025
|2024 template added
|-
|
|
|2021 template added
====CHAPTER 4 (TUMOURS OF THE NIPPLE)====
|-
|CHAPTER 4 (TUMOURS OF THE NIPPLE)
|
|
----
----
Line 459: Line 511:
----
----
|-
|-
|Syringomatous tumour||Disease||
|[[BRST5:Syringomatous tumour|Syringomatous tumour]]||Disease||
|
|
|
|
Line 468: Line 520:
|
|
|-
|-
|Nipple adenoma||Disease||
|[[BRST5:Nipple adenoma|Nipple adenoma]]||Disease||
|
|
|
|
Line 477: Line 529:
|
|
|-
|-
|Paget disease of the breast||Disease||
|[[BRST5:Paget disease of the breast|Paget disease of the breast]]||Disease||Aamer Ahmed Fairoze (trainee), Katherine Geiersbach as mentor
|
|2/20/2026
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
|-
|
|
|-
====CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST)====
|CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST)
|
|
----
----
Line 506: Line 559:
----
----
|-
|-
|Haemangioma||Disease||
|[[BRST5:Haemangioma|Haemangioma]]||Disease||
|
|
|
|
Line 515: Line 568:
|
|
|-
|-
|Angiomatosis||Disease||
!'''Disease'''
!'''Page Type'''
!'''<span style="color:#0070C0">Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Angiomatosis|Angiomatosis]]||Disease||
|
|
|
|
Line 524: Line 588:
|
|
|-
|-
|Atypical vascular lesions||Disease||
|[[BRST5:Atypical vascular lesions|Atypical vascular lesions]]||Disease||
|
|
|
|
Line 533: Line 597:
|
|
|-
|-
|Postradiation angiosarcoma of the breast||Disease||
|[[BRST5:Postradiation angiosarcoma of the breast|Postradiation angiosarcoma of the breast]]||Disease||
|
|
|
|
Line 542: Line 606:
|
|
|-
|-
|Primary angiosarcoma of the breast||Disease||
|[[BRST5:Primary angiosarcoma of the breast|Primary angiosarcoma of the breast]]||Disease||
|
|
|
|
Line 551: Line 615:
|
|
|-
|-
|Nodular fasciitis||Disease||
|[[BRST5:Nodular fasciitis|Nodular fasciitis]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|N/A
|N/A
|
|
|-
|[[BRST5:Myofibroblastoma|Myofibroblastoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|[[BRST5:Desmoid fibromatosis|Desmoid fibromatosis]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|-
|Myofibroblastoma||Disease||
|[[BRST5:Inflammatory myofibroblastic tumour|Inflammatory myofibroblastic tumour]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|Migrated page to STBT5.
|-
|-
|Desmoid fibromatosis||Disease||
|[[BRST5:Schwannoma|Schwannoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[BRST5:Inflammatory Myofibroblastic Tumour|Inflammatory myofibroblastic tumour]]||Disease||Yajuan Liu
|[[BRST5:Neurofibroma|Neurofibroma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|8/11/2023
|N/A
|11/11/2023
|N/A
|COMPLETE
|N/A
|N/A
|N/A
|N/A
|
|
|Katherine Geiersbach
|12/6/2023
|2021 template added
|-
|-
|Schwannoma||Disease||
!'''Disease'''
|
!'''Page Type'''
|
!'''<span style="color:#0070C0">Author'''
|
!'''Date Assigned to Author'''
|
!'''Target Completion Date'''
|
!'''Author Content (Pending or Complete)'''
|
!'''Date Completed by Author'''
|
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|-
|Neurofibroma||Disease||
|[[BRST5:Granular cell tumour|Granular cell tumour]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|Granular cell tumour||Disease||
|[[BRST5:Leiomyoma|Leiomyoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|Leiomyoma||Disease||
|[[BRST5:Leiomyosarcoma|Leiomyosarcoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|Leiomyosarcoma||Disease||
|[[BRST5:Lipoma|Lipoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|Lipoma||Disease||
|[[BRST5:Angiolipoma|Angiolipoma]]||Disease||[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|Angiolipoma||Disease||
|[[BRST5:Liposarcoma|Liposarcoma]]||Disease||
|
|
|
|
Line 650: Line 734:
|
|
|-
|-
|Liposarcoma||Disease||
|[[BRST5:Pseudoangiomatous stromal hyperplasia|Pseudoangiomatous stromal hyperplasia]]||Disease||
|
|
|
|
Line 659: Line 743:
|
|
|-
|-
|Pseudoangiomatous stromal hyperplasia||Disease||
|
|
|
====CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST)====
|
|
|
|
|
|-
|CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST)
|
|
----
----
Line 688: Line 764:
----
----
|-
|-
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)||Disease||
|[[BRST5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|N/A
|
|
|-
|[[BRST5:Follicular lymphoma|Follicular lymphoma]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|-
|Follicular lymphoma||Disease||
!'''Disease'''
|
!'''Page Type'''
|
!'''<span style="color:#0070C0">Author'''
|
!'''Date Assigned to Author'''
|
!'''Target Completion Date'''
|
!'''Author Content (Pending or Complete)'''
|
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|-
|Diffuse large B-cell lymphoma||Disease||
|[[BRST5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|Burkitt lymphoma||Disease||
|[[BRST5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease||
|
|
|
|
|
|
====CHAPTER 7 (TUMOURS OF THE MALE BREAST)====
|
|
|-
|CHAPTER 7 (TUMOURS OF THE MALE BREAST)
|
|
----
----
Line 753: Line 841:
----
----
|-
|-
|Gynaecomastia||Disease||
|[[BRST5:Gynaecomastia|Gynaecomastia]]||Disease||
|
|
|
|
Line 762: Line 850:
|
|
|-
|-
|Carcinoma in situ||Disease||
|[[BRST5:Carcinoma in situ|Carcinoma in situ]]||Disease||
|
|
|
|
Line 771: Line 859:
|
|
|-
|-
|Invasive carcinoma||Disease||
|[[BRST5:Invasive carcinoma|Invasive carcinoma]]||Disease||
|
|
|
|
Line 780: Line 868:
|
|
|-
|-
|Metastases to the breast||Disease||
|[[BRST5:Metastases to the breast|Metastases to the breast]]||Disease||
|
|
|
|
Line 789: Line 877:
|
|
|-
|-
|CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST)
|
====CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST)====
|
|
----
----
Line 809: Line 898:
----
----
|-
|-
|BRCA1/2-associated hereditary breast and ovarian cancer syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:BRCA1/2-associated hereditary breast and ovarian cancer syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 818: Line 907:
|N/A
|N/A
|-
|-
|Cowden syndrome||Disease||
!'''Disease'''
|
!'''Page Type'''
|
!'''<span style="color:#0070C0">Author'''
|
!'''Date Assigned to Author'''
|
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''
!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|[[BRST5:Cowden syndrome|Cowden syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship statu]]<nowiki/>s [see [[GTS5:PTEN hamartoma tumour syndrome (PTEN)|PTEN hamartoma tumour syndrome (PTEN)]]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|NOT YET CREATED (not in GTS5) - See page "[[DIG5:Cowden syndrome|Cowden Syndrome]]" in DIG5 book. Will later add breast book link redirecting to this DIG5 book page (need to correlate with related volunteer page - [[DIG5:Volunteer Assignments and Opportunities]]).
|-
|-
|Ataxia-telangiectasia||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
Line 835: Line 934:
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|Li-Fraumeni syndrome, TP53-associated||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Li-Fraumeni syndrome, TP53-associated|Li-Fraumeni syndrome, TP53-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
Line 844: Line 943:
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Li-Fraumeni syndrome, CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|[[BRST5:CDH1-associated breast cancer|CDH1-associated breast cancer]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 853: Line 960:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|CDH1-associated breast cancer||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:PALB2-associated cancers|PALB2-associated cancers]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
Line 862: Line 970:
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|PALB2-associated cancers||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[BRST5:Peutz-Jeghers syndrome|Peutz-Jeghers syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
|N/A
Line 871: Line 979:
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|Peutz-Jeghers syndrome||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis type 1]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|N/A
|N/A
|N/A
|N/A
Line 879: Line 988:
|N/A
|N/A
|N/A
|N/A
|N/A
|-
|Neurofibromatosis type 1||Disease||Ngoni Faya (trainee) + Madina Sukhanova
|
|
|
|
|
|
|
|NOT YET CREATED - See page "[[GTS5:Neurofibromatosis type 1 (NF1)|Neurofibromatosis Type 1 (NF1)]]" in GTS5 book. Will later add breast book link redirecting to this GTS5 book page (need to correlate with related volunteer page - [[GTS5:Volunteer Assignments and Opportunities]]).
|-
|-
|[[BRST5:Polygenic Component of Breast Cancer Susceptibility|Polygenic component of breast cancer susceptibility]]
|[[BRST5:Polygenic component of breast cancer susceptibility|Polygenic component of breast cancer susceptibility]]
|Disease
|Disease
|Xiaolin Hu
|Xiaolin Hu

Latest revision as of 07:45, 28 March 2026

Welcome!

For assignments, please see the "Author" column below (highlighted blue).

If empty (no name is present), please volunteer to create content for that disease!

To volunteer, please [Contact us] with your page of interest.


WHO Classification of Tumours of the Breast (5th Edition) Content
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes

CHAPTER 2 (EPITHELIAL TUMOURS OF THE BREAST)
Usual ductal hyperplasia Disease Ritika Pathak 2/25/2026 PENDING Katherine Geiersbach
Columnar cell lesions, including flat epithelial atypia Disease
Atypical ductal hyperplasia Disease
Sclerosing adenosis Disease
Apocrine adenosis and adenoma Disease
Microglandular adenosis Disease
Radial scar/complex sclerosing lesion Disease
Tubular adenoma Disease
Lactating adenoma Disease Joanna George 3/28/2026 PENDING Katherine Geiersbach
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Ductal adenoma Disease
Pleomorphic adenoma Disease
Adenomyoepithelioma Disease
Malignant adenomyoepithelioma Disease
Intraductal papilloma Disease
Papillary ductal carcinoma in situ Disease Sresi Singh (trainee), Katherine Geiersbach 2/26/2026 PENDING Katherine Geiersbach
Encapsulated papillary carcinoma Disease
Solid papillary carcinoma (in situ and invasive) Disease
Invasive papillary carcinoma Disease
Atypical lobular hyperplasia Disease
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Lobular carcinoma in situ Disease Vaishnavi Devarakonda 2/19/2026 PENDING Katherine Geiersbach
Ductal carcinoma in situ Disease Vaishnavi Devarakonda 2/19/2026 PENDING Katherine Geiersbach
Invasive breast carcinoma of no special type Disease Braa Elwaleed Mohamed Ahmed (trainee) +Katherine to find mentor 2/20/2026 PENDING Katherine Geirsbach
Microinvasive carcinoma Disease
Invasive lobular carcinoma Disease
Tubular carcinoma Disease Sree Vishmaya 3/20/2026 Katherine Geiersbach
Cribriform carcinoma Disease
Mucinous carcinoma Disease
Mucinous cystadenocarcinoma Disease
Invasive micropapillary carcinoma Disease
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Carcinoma with apocrine differentiation Disease
Metaplastic carcinoma Disease
Acinic cell carcinoma Disease
Adenoid cystic carcinoma Disease Katherine Geiersbach;

Jun Liao

10/12/02022 11/11/2023 COMPLETE Katherine Geiersbach 4/16/2025 2024 template added
Secretory carcinoma Disease Hui Chen;

Katherine Geiersbach

10/12/2022 11/11/2023 COMPLETE Katherine Geiersbach 4/16/2025 2024 template added
Mucoepidermoid carcinoma Disease
Polymorphous adenocarcinoma Disease
Tall cell carcinoma with reversed polarity Disease H. Evin Gulbahce 8/11/2023 10/11/2023 COMPLETE Katherine Geiersbach 4/16/2025 2024 template added
Neuroendocrine tumour Disease
Neuroendocrine carcinoma Disease
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes

CHAPTER 3 (FIBROEPITHELIAL TUMOURS AND HAMARTOMAS OF THE BREAST)
Hamartoma Disease
Fibroadenoma Disease Aamer Ahmed Fairoze (trainee), Katherine Geiersbach as mentor 2/20/2026 PENDING Katherine Geiersbach
Phyllodes tumour Disease Emilie Lalonde;

H. Evin Gulbahce;

Katherine Geiersbach

8/11/2023 11/11/2023 COMPLETE 1/8/2025 2024 template added

CHAPTER 4 (TUMOURS OF THE NIPPLE)
Syringomatous tumour Disease
Nipple adenoma Disease
Paget disease of the breast Disease Aamer Ahmed Fairoze (trainee), Katherine Geiersbach as mentor 2/20/2026 PENDING Katherine Geiersbach

CHAPTER 5 (MESENCHYMAL TUMOURS OF THE BREAST)
Haemangioma Disease
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Angiomatosis Disease
Atypical vascular lesions Disease
Postradiation angiosarcoma of the breast Disease
Primary angiosarcoma of the breast Disease
Nodular fasciitis Disease See STBT5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Myofibroblastoma Disease See STBT5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Desmoid fibromatosis Disease See STBT5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Inflammatory myofibroblastic tumour Disease See STBT5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A Migrated page to STBT5.
Schwannoma Disease See STBT5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Neurofibroma Disease See STBT5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Granular cell tumour Disease See STBT5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Leiomyoma Disease See STBT5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Leiomyosarcoma Disease See STBT5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Lipoma Disease See STBT5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Angiolipoma Disease See STBT5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Liposarcoma Disease
Pseudoangiomatous stromal hyperplasia Disease

CHAPTER 6 (HAEMATOLYMPHOID TUMOURS OF THE BREAST)
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) Disease See HAEM5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Follicular lymphoma Disease See HAEM5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Diffuse large B-cell lymphoma Disease See HAEM5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Burkitt lymphoma Disease See HAEM5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Breast implant-associated anaplastic large cell lymphoma Disease See HAEM5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A

CHAPTER 7 (TUMOURS OF THE MALE BREAST)
Gynaecomastia Disease
Carcinoma in situ Disease
Invasive carcinoma Disease
Metastases to the breast Disease

CHAPTER 8 (GENETIC TUMOUR SYNDROMES OF THE BREAST)
BRCA1/2-associated hereditary breast and ovarian cancer syndrome Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A N/A
Disease Page Type Author Date Assigned to Author Target Completion Date Author Content (Pending or Complete) Date Completed by Author Associate Editor Date of Last Editor Review Notes
Cowden syndrome Disease See GTS5 volunteer sheet for authorship status [see PTEN hamartoma tumour syndrome (PTEN)] N/A N/A N/A N/A N/A N/A
Ataxia-telangiectasia Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Li-Fraumeni syndrome, TP53-associated Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Li-Fraumeni syndrome, CHEK2-associated Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
CDH1-associated breast cancer Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
PALB2-associated cancers Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Peutz-Jeghers syndrome Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Neurofibromatosis type 1 Disease See GTS5 volunteer sheet for authorship status N/A N/A N/A N/A N/A N/A
Polygenic component of breast cancer susceptibility Disease Xiaolin Hu 6/4/2024 Template added (6/4/24)


Retrieved from "https://content.ccga.io/index.php?title=BRST5:Volunteer_Assignments_and_Opportunities&oldid=21057"